Repligen Corp
ISIN US7599161095
|WKN 870980
Overview
Description
Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the North America. Europe, and Asia Pacific Region or Other geographical segments. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.
Healthcare Healthcare Services Miscellaneous Healthcare United States
Financials
Key metrics
| Market capitalisation, EUR | 6,608.71 m |
| EPS, EUR | -0.42 |
| P/B ratio | 3.65 |
| P/E ratio | 546.75 |
| Dividend yield | 0.00% |
Income statement (2024)
| Revenue, EUR | 586.52 m |
| Net income, EUR | -23.59 m |
| Profit margin | -4.02% |
What ETF is Repligen Corp in?
There are 41 ETFs which contain Repligen Corp. All of these ETFs are listed in the table below. The ETF with the largest weighting of Repligen Corp is the First Trust NYSE Arca Biotechnology UCITS ETF Acc.
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
